<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="547">
  <stage>Registered</stage>
  <submitdate>25/03/2005</submitdate>
  <approvaldate>25/03/2005</approvaldate>
  <nctid>NCT00106561</nctid>
  <trial_identification>
    <studytitle>Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney</studytitle>
    <scientifictitle>A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>RMH2001-142</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Disease</healthcondition>
    <healthcondition>Diabetic Nephropathy</healthcondition>
    <healthcondition>Glomerulonephritis</healthcondition>
    <healthcondition>Proteinuria</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Spironolactone
Treatment: drugs - Irbesartan

Treatment: drugs: Spironolactone


Treatment: drugs: Irbesartan


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>percent reduction in 24 hour urine protein excretion</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Proteinuria more than 1.5 g/day

          -  On ACEI for more than 6 months

          -  Serum creatinine less than 200 micromol/L with less than 20% variability in the
             preceeding 3 months

          -  Creatinine clearance more than 30 ml/min, with less than 20% variability in the
             preceeding 3 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Serum potassium level more than 5 mmol/L

          -  Treatment with corticosteroids, NSAID or immunosuppressant medication

          -  Acute myocardial infarction or cerebrovascular accident in the previous 6 months

          -  Severe uncontrolled hypertension (diastolic &gt; 115 mmHg or systolic BP [blood pressure]
             &gt; 220 mmHg)

          -  Evidence or suspicion of renovascular disease, obstructive uropathy, collagen disease,
             cancer, drug or alcohol abuse, pregnancy, or breast feeding and ineffective
             contraception</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Department of Nephrology, The Royal Melbourne Hospital - Melbourne</hospital>
    <postcode>3050 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine which combination of the tablets ramipril,
      irbesartan or spironolactone is best to lower protein leakage from the kidney.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00106561</trialwebsite>
    <publication>Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001 Sep 20;345(12):925-6.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gavin G Becker, MBBS MD</name>
      <address>Director Department of Nephrology, The Royal Melbourne Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>